Clinical Trials
Wet Age Related Macular Degeneration
Active Studies
AAVIATE (RegenxBio)
A Phase 2, Randomized, Dose-escalation, Ranibizumab-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of RGX-314 Gene Therapy Delivered via One or Two Suprachoroidal Space (SCS) Injections in Participants with Neovascular Age-Related Macular Degeneration (nAMD).
ATMOSPHERE (RegenxBio)
A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD.
LTFU nAMD (RegenxBio)
A Long-term Follow-Up Study to Evaluate the Safety and Efficacy of Suprachoroidal Administration of RGX-314 for Participants with Neovascular Age-Related Macular Degeneration
NOVA-1 (Alcon Aerie)
A Phase 1/2 Two-Stage Dose Escalation and Randomized Parallel Group Study to Evaluate the Safety, Preliminary Treatment Effects, and Durability of AR-14034 Sustained Release Implant Compared to Intravitreal Anti-Vascular Endothelial Growth Factor Treatment in Participants with Neovascular Age-Related Macular Degeneration
ODYSSEY (Clearside)
A Phase 2b Study Of Suprachoroidally Administered CLS-AX In Participants With Neovascular Age-related Macular Degeneration
PORTAL (Genentech Roche)
A Multicenter, Open-label Extension Study To Evaluate The Long-term Safety And Tolerability Of The Port Delivery System With Ranibizumab In Patients With Neovascular Age-related Macular Degeneration.
SHORE (Opthea)
A Phase 3, Multicentre, Double-masked, Randomised Study To Evaluate The Efficacy And Safety Of Intravitreal OPT-302 In Combination With Ranibizumab, Compared With Ranibizumab Alone, In Participants With Neovascular Age-related Macular Degeneration (NAMD)
Completed Studies
ALTISSIMO (Graybug)
A Phase 2b Multicenter Dose-Ranging Study Evaluating the Safety and Efficacy of a Long-acting Intravitreal Sunitinib Malate Depot Formulation (GB-102) Compared to Intravitreal Aflibercept in Subjects with Neovascular (Wet) Age-related Macular Degeneration (ALTISSIMO Study)
ANCHOR (Genentech)
Phase 3 Double Masked Active Treatment Of The Efficacy And Safety Of Ranibizumab (Lucentis) Compared To Visudyne For The Treatment Of Wet AMD.
AVANTE (Santen)
A 21-month, Phase 2 Study On The Efficacy, And Safety Of Intravitreal Injections Of DE-122 In Combination With Lucentis Compared To Lucentis Monotherapy In Subjects With Wet Age-related Macular Degeneration.
AVONELLE-X (Roche/Genentech)
A Multicenter, Open-label Extension Study To Evaluate The Long-term Safety And Tolerability Of Faricimab In Patients With Neovascular Age-related Macular Degeneration.
CABERNET (Neovista)
Phase 3 Study For The Use Of Radiation With The Epi-rad 90 System To Treat Wet AMD.
CANDELA (Regeneron)
A Randomized, Single-masked, Active-controlled Phase 2 Study Of The Safety, Tolerability, And Efficacy Of Repeated Doses Of High-dose Aflibercept In Patients With Neovascular Age-related Macular Degeneration.
CAPELLA (Regeneron)
A 1 Year, Phase 2, Double-masked, Randomized, Controlled, Multiple-dose, Regimen-ranging Study Of The Efficacy And Safety Of Intravitreal REGN2176-3 In Patients With Neovascular Age-related Macular Degeneration.
CEDAR (Allergan)
A 2 Year, Phase 3 Study On The Safety And Efficacy Of Abicipar Pegol (AGN-150998) In Patients With Neovascular Age-related Macular Degeneration.
DAVIO (Eyepoint)
A Phase 1, Multicenter, Prospective, Open-Label, Dose Escalation Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), in Subjects with Wet AMD.
DAZZLE (Kodiak Sciences)
A Phase 2, Prospective, Randomized, Double-masked, Active Comparatorcontrolled, Multi-center Study to Investigate the Efficacy and Safety of Repeated Intravitreal Administration of KSI-301 in Subjects with Neovascular (Wet) Age-related Macular Degeneration
ECLIPSE (Ophthotech)
A 2 Year Phase 3 study To Determine The Safety And Efficacy Of E10030 (Fovista) in Combination With Ranibizumab (Lucentis) Compared To Ranibizumab (Lucentis) Monotherapy In Wet AMD.
EMERGE (Iconic Therapeutics)
A 6 Month, Phase 2, Randomized, Double-masked, Multicenter, Active-controlled Study Evaluating Administration Of Repeated Intravitreal Doses Of Hi-con1 In Patients With Choroidal Neovascularization Secondary To Age-related Macular Degeneration.
HARBOR (Genentech)
Phase 3 Randomized Treatment Study Of The Efficacy And Safety Of Different Doses Of Ranibizumab (Lucentis) Administered Monthly Or As Needed.
HAWK (Alcon)
A Phase 3, Two-year, Randomized, Double-masked, Multicenter, Three-arm Study Comparing The Efficacy And Safety Of RTH258 Versus Aflibercept In Subjects With Neovascular Age-related Macular Degeneration.
HORIZON (Genentech)
Follow Up Study To Evaluate The Safety And Tolerability Of Ranibizumab (Lucentis).
KSI-CL-101 (Kodiak Sciences)
A Phase 1b Open Label, Multi-center Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects with Wet Age-related Macular Degeneration, Diabetic Macular Edema, and Retinal Vein Occlusion.
LADDER (Genentech)
A 20 Month, Phase 2, Multicenter, Randomized, Active Treatment-controlled Study Of The Efficacy And Safety Of The Ranibizumab Port Delivery System For Sustained Delivery Of Ranibizumab In Patients With Subfoveal Neovascular Age-related Macular Degeneration.
LUCERNE GR40844 (Roche)
A Phase 3, Multicenter, Randomized, Double-masked, Active Comparator-controlled Study To Evaluate The Efficacy And Safety Of Faricimab In Patients With Neovascular Age-related Macular Degeneration.
MAPLE 1771-201-008 (Allergan)
Evaluation Of Abicipar Pegol In Patients With Neovascular Age-related Macular Degeneration.
MARINA (Genentech)
Phase 3 Double Masked Active Treatment Controlled Study Of The Efficacy And Safety Of Ranibizumab (Lucentis).
MERLIN CRTH258AUS04 (Novartis)
A Multicenter, Randomized, Double-masked, Phase 3a Study To Assess Safety And Efficacy Of Brolucizumab 6 Mg Q4 Weeks Compared To Aflibercept 2 Mg Q4 Weeks In Patients With Neovascular Age-related Macular Degeneration With Persistent Retinal Fluid.
NEXUS (Lpath)
A 9 Month Phase 2A Study That Is Evaluating ISONEP As Either Monotherapy Or Adjunctive Therapy To Ranibizumab (Lucentis), Bevacizumab (Avastin) Or Aflibercept (Eylea).
OASIS (Clearside)
Open-label, Dose-escalation, Phase 1/2a Study Of The Safety And Tolerability Of Suprachoroidally Administered Cls-ax Following Intravitreal Anti-vegf Therapy In Subjects With Neovascular Age-related Macular Degeneration.
ONYX (Regeneron)
A 9 Month, Randomized, Double-masked, Active-controlled Phase 2 Study Of The Efficacy, Safety, And Tolerability Of Repeated Doses Of Intravitreal REGN910-3 In Patients With Neovascular Age-related Macular Degeneration.
OPH1004 (Ophthotech)
A 2 Year, Phase2, Randomized, Double-masked, Controlled Trial To Establish The Safety And Efficacy Of Intravitreous Administration Of FOVISTA (Anti PDGF-B Pegylated Aptamer) Administered In Combination With Either Avastin Or Eylea Compared To Avastion Or Eylea Monotherapy In Subjects With Subfoveal Neovascular Age-related Macular Degeneration.
OSPREY (Alcon)
A 1 Year Phase 2 Study That Will Determine The Safety, Tolerability And Efficacy Of ESBA 1008 Vs Aflibercept (Eylea) In Wet AMD.
OWL (Alcon)
A 2 Month Phase 2 Study To Evaluate The Effect Of ESBA 1008 Applied By Microvolume Injection Or Infusion In wet AMD.
PANDA KHB-1801 (Chengdu Kanghong Biotechnology)
A Multicenter, Double-masked, Randomized, Dose-ranging Trial To Evaluate The Efficacy And Safety Of Conbercept Intravitreal Injection In Subjects With Neovascular Age-related Macular Degeneration.
PAVE (Santen)
A 3 Month, Phase 1, Open-label, Dose-escalating, Sequential-cohort Study Assessing The Safety, Tolerability, Immunogenicity, And Bioactivity Of A Single Intravitreal Injection Of DE-122 Injectable Solution For The Treatment Of Refractory Exudative Age-related Macular Degeneration.
PULSAR (Regeneron)
Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration.
REACH Stage 2 (Allergan)
Phase 2 Study Of The Safety And Efficacy Of AGN-150998 Versus Ranibizumab (Lucentis) In Treatment-naive Patients With Advanced AMD.
REACH Stage 3 (Allergan)
A 6 Month Phase 2 Study Of The Safety And Efficacy Of AGN-150998 Vs Ranibizumab (Lucentis) In Treatment-naive Patients With wet AMD.
RESCUE (NCRVA & Genentech)
A 1 Year Study Evaluating Ranibizumab (Lucentis) In Wet AMD Patients Previously Treated With Bevacizumab (Avastin) AND Aflibercept (Eylea).
SAILOR (Genentech)
A Comparative Study Evaluating The Different Doses Of Ranibizumab (Lucentis).
SEE (Alcon)
Phase 2 Study Of The Safety, Tolerability And Efficacy Of ESBA 1008 Versus Ranibizumab (Lucentis) In Advanced AMD.
SF0166-C-002(SciFluor Life Sciences)
A Phase I/II,2 Month, Randomized, Double-masked, Multicenter Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of SF0166, Topical Ophthalmic Solution In The Treatment Of Neovascular Age-related Macular Degeneration.
TAP (Novartis)
Phase 3 Study Of The Efficacy And Safety Of Verteporfin With Photodynamic Therapy For The Treatment Of Wet AMD.
VIEW (Regeneron)
Phase 3 Study Of The Efficacy, Tolerability And Safety Of Repeated Doses Of Aflibercept (Eylea).
VIEW EXTENSION (Regeneron)
Follow Up Study For The Patients Treated With Aflibercept (Eylea) For Wet AMD In The VIEW Study.
